Carlumab/CNTO888 (a human recombinant mAb targeting CCL2) entered phase I and II trials for patients with solid tumors, including metastatic castrate-resistant prostate cancer (NCT00992186 and NCT01204996), but despite being well-tolerated, it failed to affect tumor growth significantly, and the drug was discontinued. The gene discussed is CCL2; the disease is neoplasm.